CYP19A1 and breast cancer: In this RCT including survivors of breast cancer with GSM undergoing treatment with aromatase inhibitors, the subjective and objective outcomes of most participants in both groups improved in symptom severity, sexuality, and vaginal tissue characteristics at the 6-month follow-up .